Bio-Techne TECH Business Segments
| TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Diagnostics And Spatial Biology | $335.93M-3.3% | $339.57M-1.7% | $342.53M+1.7% | $346.26M+6.1% | $347.24M+12.4% | |
| Protein Sciences | $869.9M+1.4% | $871.43M+3.2% | $867.9M+4.5% | $870.24M+4.7% | $857.76M+2.1% | |
| Revenue by Product | ||||||
| Consumables | $977.32M+1.3% | $977.77M+2.5% | $973.04M+4.1% | $972.29M+4.8% | $965.12M+4.3% | |
| Instruments | $108M-2.1% | $106.44M-3.8% | $107.71M-1.7% | $112.09M+3.5% | $110.28M+1.1% | |
| Royalty | $24.63M+6.0% | $24.7M+7.9% | $24.29M+8.8% | $23.69M+1.5% | $23.24M0.0% | |
| Service | $100.86M-8.4% | $106.66M-1.6% | $111.7M+6.2% | $111.57M+12.4% | $110.13M+14.4% | |
| Revenue by Geography | ||||||
| APAC Excluding Greater China | $82.6M+6.4% | $82.02M+9.9% | $78.29M+4.8% | $77.26M+4.5% | $77.64M+7.5% | |
| CN | $104.06M+6.7% | $102.53M+4.0% | $100.93M+2.7% | $100.46M+1.0% | $97.48M-3.8% | |
| EMEA Excluding UK | $284.28M+9.5% | $277.33M+9.4% | $272.37M+10.9% | $266.31M+10.3% | $259.52M+9.1% | |
| GB | $56.61M+9.3% | $54.57M+0.9% | $54.09M+5.0% | $54.83M+9.6% | $51.8M+0.9% | |
| Rest Of World | $37.61M-0.9% | $39.02M-0.9% | $37.6M-0.4% | $37.55M+2.9% | $37.95M+3.9% | |
| US | $645.66M-5.7% | $660.11M-2.3% | $673.46M+1.5% | $683.23M+3.9% | $684.38M+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Techne break its business down?
- Bio-Techne (TECH) reports revenue by business across 2 parts — Diagnostics And Spatial Biology and Protein Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Techne's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Techne's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
